CLINICAL TRIALS PROFILE FOR TRAVOPROST
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Travoprost
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00670033 ↗ | Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension | Completed | Alcon Research | Phase 2 | 2008-04-01 | The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension. |
| New Formulation | NCT01452009 ↗ | Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004% | Withdrawn | Alcon Research | Phase 3 | 2011-11-01 | A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004% |
| New Formulation | NCT01658839 ↗ | Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients | Completed | Alcon Research | Phase 1 | 2013-01-01 | The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Travoprost
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00051142 ↗ | A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) | Completed | Alcon Research | Phase 3 | 2001-02-01 | The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension. |
| NCT00051181 ↗ | A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma | Completed | Alcon Research | Phase 3 | 2000-01-01 | To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma. |
| NCT00061503 ↗ | Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension | Completed | Alcon Research | Phase 4 | 2003-04-01 | The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Travoprost
Condition Name
Clinical Trial Locations for Travoprost
Trials by Country
Clinical Trial Progress for Travoprost
Clinical Trial Phase
Clinical Trial Sponsors for Travoprost
Sponsor Name
